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Abstract
Background: The aim of the study was to evaluate the prognostic power of new classifications of N descriptor
created basing on the number (NLN) and the ratio of metastatic lymph nodes (RLN) in NSCLC compared to the
current classification (CLN).
Methods: The data of 529 patients with NSCLC operated with the intention of radical resection, were analyzed. The
new categories of N descriptor were created as follows: 1) NLN - median number of metastatic nodes was 3, thus
in NLN0 the number of metastatic nodes =0, in NLN1 1-2, in NLN2 ≥ 3, 2) RLN - median ratio (number of metastatic
lymph nodes to all nodes removed) was 12.4 %, thus in RLN0 the ratio was 0, in RLN1 < 13 %, in RLN2 > 13 %. The
prognostic value of each classification was calculated on the basis of hazard ratios defined in multivariate Cox
proportional hazard model.
Results: The new classifications of N descriptor turned out to be an independent strong prognostic factor (p <0.001)
with a 5-year survival rate NLN0-62 %, NLN1-39 %, NLN2-26 % and RLN0-62 %, RLN1-37 % and RLN2-26 %. For 5-year
survival rates in CLN0-62 %, CLN1-42 %, CLN2-24 % (p < 0.001), a higher prognostic value of new classifications was not
demonstrated, the hazard ratio amounted to 2.22, 2.08, 2.49 for NLN2, RLN2 and CLN2 respectively.
Conclusion: Despite the significantly high prognostic power, the new classifications cannot be considered superior over
CLN. There are some deficiencies in the current classification, therefore further studies on its improvement are needed.
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Background
Despite the high heterogeneity of N descriptor, its
classification in NSCLC has remained unchanged since
1987, when the fourth edition of the TNM classification
was published [1]. The heterogeneity of N descriptor
refers mainly to metastases in mediastinal lymph nodes
(N2) where we can identify patients with a single meta-
static node within one node station, several metastatic
nodes in one node station, multi-level N2 disease and
patients with “bulky disease”. According to many reports,
the prognosis in these groups, as well as an approach to a
surgical management being a part of multimodality
therapy or disqualification from the operation, may be
different [2–4]. The heterogeneity of N descriptor causes
that the spread of neoplastic processes to mediastinal
lymph nodes, frequently excluding intrapulmonary nodal
groups and a pulmonary hilum (skipping metastasis) is
unsymmetrical and difficult to predict. According to some
reports, the prognosis of patients with N2 but negative
N1 is better than of patients with a positive N2 and N1
simultaneously [5]. The classifications of N descriptor
in NSCLC appearing successively, however, are based
on the location of lymph nodes and assume the sym-
metrical spread of the cancer.
Therefore, due to the differences in the prognosis asso-
ciated with heterogeneity of N2 descriptor, it should be
considered whether to classify lymph nodes in NSCLC
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depending on the number of metastatic nodes or on the
ratio of the number of resected nodes to metastatic nodes.
A similar assumption has been adopted for instance in
staging a colorectal, gastric and breast cancer in which the
number of metastatic lymph nodes has been considered
one of the elements staging N descriptor [6]. It is also sug-
gested that the ratio determining the number of metastatic
lymph nodes, particularly relating to a breast, bladder,
colorectal cancer may have a significant prognostic
value in the classification of N descriptor [7–9].
The aim of the paper is to evaluate the prognostic
value of classifications based on the number of meta-
static lymph nodes (NLN) and on the ratio of the
number of resected nodes to metastatic nodes (RLN)
compared to the current classification of N descriptor
(CLN) in NSCLC.
Methods
The data of 700 patients with lung cancer subsequently
operated with the intention of radical resection, were
analyzed. All patients were treated surgically between 1
January 2007 and 1 July 2009 in one, high volume thoracic
surgery center. Data for statistical analyzes were obtained
from the National Lung Cancer Registry. To eliminate
factors which may additionally affect or do affect the prog-
nosis, 92 patients after limited resections (wedge resection
or segmentectomy), 7 patients with carcinoid tumor, 7
patients with small cell lung cancer, 14 patients with R1
resection, 3 patients with M1 and 13 perioperative deaths
were excluded from the study. In addition, 35 patients
with removed nodes <6 were excluded because the re-
moval of at least 6 nodes is recommended to perform
proper staging of N descriptor [10]. Finally, a group of 529
patients remained whose data were further analyzed.
Before taking a decision on a surgical treatment, all
the patients had a chest radiography, chest computed
tomography (CT), bronchoscopy, abdominal ultrasound
and CT/MRI of the central nervous system, in case of
neurological symptoms. Positron emission tomography
(PET-CT) was performed in case of doubts, before the
invasive diagnosis of mediastinal lymph nodes and in
case of the diagnosis of mediastinal and peripheral
changes in the suspicion of metastases. In case of suspi-
cion of metastases to mediastinal lymph nodes during
preoperative imaging (>1 cm diameter in a short axis) a
videomediastinoscopy or a transtracheal/transbronchial
biopsy was performed without ultrasound guidance
(TBNA). Endobronchial ultrasound (EBUS) and endo-
scopic oesophageal ultrasound (EUS) were not per-
formed as there were just introduced into the diagnosis
of mediastinal lymphadenopathy. The surgical treatment
in the studied group of patients included anatomical re-
section of the lung parenchyma (lobectomy, bilobectomy,
pneumonectomy) and systematic mediastinal lymph node
dissection with “en bloc” resection of right paratracheal
2R and 4R nodes. Nodes of 4 L, 5, 6, 7, 8, 9, 10 and 11
groups were removed separately. Intrapulmonary nodes of
12 group were removed together with a lobe, then care-
fully resected and evaluated by a histopathologist. The
mediastinal lymph nodes were resected “en bloc” with the
fatty tissue of mediastinum wherever it was possible to
avoid defragmentation and were divided on the operating
table, then each lymph node was sent for histopathological
examination in a separate box. If the lymph node was dis-
integrated during harvesting the pieces were sent to evalu-
ation in one box as a one lymph node. Pathological
staging was evaluated on the basis of the current seventh
edition of the TNM, all the stages were revised from the
pathology reports and the Polish National Lung Cancer
Registry.
The postoperative follow-up included radiological
examination every 3 months for the first two years, then
every 6 months for 3 next years, and once a year after-
wards. Every 6 months, a control chest CT scan was
performed. Median follow-up for the entire group was
61 months.
New categories of N descriptor were created in the
following manner:
1) the classification based on the number of metastatic
lymph nodes (NLN)
Median number of metastatic lymph nodes
was 3 (1 to 25). The median enables to
create a boundary line between new NLN1
descriptor and NLN2. Thus, in patients with
NLN0 descriptor the number of metastatic
lymph nodes = 0, with NLN1 the number of
metastatic lymph nodes <3 and with NLN2 ≥ 3
metastatic nodes.
2) the classification based on the ratio of metastatic
lymph nodes (RLN)
The ratio determines the quotient of metastatic
lymph nodes to all nodes removed during the
operation. The median of the calculated ratios
was 12.4 % (2.2 % to 70 %). For patients with
a RLN0 descriptor the ratio was 0, for patients
with RLN1 < 13 %, for patients with
RLN2 > 13 %.
The prognostic value of each classification was calcu-
lated on the basis of hazard ratios defined in the multi-
variate Cox proportional hazard model. The survival
curves were plotted using Kaplan-Meier method and
the differences in survival were determined using a log-
rank test. Wilcoxon and χ2 tests were used to compare
the clinical data. P <0.05 was considered statistically
significant. STATISTICA software, version 10, StatSoft
Inc. was used for statistical analyses.
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Results
Patient records including demographic, surgical and
pathological data are presented in Table 1. On average,
during the operation 23.4 nodes were resected (6 – 71).
Among 529 patients included in the study, 377 (71.3 %)
had no metastases in the resected lymph nodes. Postop-
erative chemotherapy was used in 45 patients with N1
descriptor (72 %) and in 56 patients with N2 (62 %),
furthermore postoperative radiotherapy was used in 15
patients with N2 descriptor (17 %). Finally 36 patients
(23 %) with N1 or N2 disease did not receive adjuvant
therapy mainly because of inadequate performance status
after surgery or other contraindications or a refusal of the
further treatment.
In 9 patients (1.7 %) a tumor was resected with the chest
wall, in 11 patients (2.1 %) bronchial sleeve resection was
performed, in 4 (0.7 %) artery sleeve resection, in 11
(2.1 %) wedge resection of another lobe on the same side.
Mean greatest dimension of a tumor was 40.6 mm.
The survival according to the current and suggested
nodal classifications is presented in Table 1 and the sur-
vival curves according to CLN, NLN and RLN in Figs. 1,
2 and 3. All the studied classifications turned out to have
a strong prognostic value (p <0.001). In order to evaluate
the prognostic power of each classification, multivariate
analysis was performed including all the factors analyzed
univariately. Each of the studied nodal classifications
was included in the multivariate analysis separately and
values of hazard ratios in each analysis were compared.
The data presented in Table 2 show that despite the
small differences, the hazard ratio of the current N2 de-
scriptor is the highest and amounts to 2.49 in compari-
son with NLN2 (HR = 2.22) and RLN2 (HR = 2.08). Each
of the studied classifications in the multivariate analysis
turned out to be a statistically significant prognostic
factor but none of the newly studied classifications is su-
perior over the current one. In the multivariate analysis
it was also found that age (p < 0.001), tumor histology
(p = 0.032) and pathological T descriptor (p < 0.001) are
strong independent prognostic factors in the evaluation
of overall survival of the patients.
Discussion
Metastases to mediastinal lymph nodes are currently in-
disputable and one of the strongest prognostic factors in
a group of patients treated surgically because of non-
small cell lung cancer [11]. Despite the high variability
in N2 descriptor including patients with micrometas-
tases or “bulky disease” and patients with a single meta-
static node or multiple metastases in many nodal
stations, the classification of N descriptor has remained
unchanged for several editions of TNM. Despite the
much better methods of the preoperative evaluation of
mediastinal lymph nodes, in approximately 10–14 % of
patients N2 disease is still found in a postoperative ma-
terial [12, 13]. Moreover, many reports show that the
prognosis of operated patients with N2 descriptor may
considerably vary in the final histopathological evalu-
ation due to the heterogeneity of metastases to medi-
astinal lymph nodes [4, 14]. The last modifications of
the TNM system in certain malignancies such as
colorectal, gastric and breast cancer involving only an
anatomical classification of N descriptor incline to the
similar approach to the classification of N descriptor
in a lung cancer.
Table 1 Patient characteristics and survival according to the





95 % CI p value
Age
≤68 279 59.5 56.2–63.0 <0.001
>68 250 46.4 43.6–49.4
Sex
Male 377 50.4 47.9–53.0 0.016
Female 152 60.5 56.0–65.5
Histology
Adenocarcinoma 251 50.2 47.2–53.4 0.1
Other 278 56.1 52.9–59.5
Surgery
Lobectomy 457 55.1 52.7–57.7 0.01
Pneumonectomy 72 41.7 37.1–46.8
pT
pT1a 72 72.2 65.0–80.2 <0.001
pT1b 69 78.3 70.9–86.4
pT2a 219 54.8 51.3–58.5
pT2b 69 46.4 41.1–52.3
pT3 93 23.7 21.7–25.8
pT4 7 28.6 18.8–43.4
CLN
CLN0 377 62 59.1–65.2 p < 0.001
CLN1 62 42 37.0–47.5
CLN2 90 24 22.3–26.7
NLN
NLN0 377 62 59.1–65.2 p < 0.001
NLN1 70 39 34.3–43.3
NLN2 82 26 23.3–28.2
RLN
RLN0 377 62 59.1–65.2 p < 0.001
RLN1 76 37 33.0–41.1
RLN2 76 26 23.8–29.1
CI confidence interval, CLN current nodal classification, NLN new classification
based on the number of metastatic lymph nodes, RLN new classification based
on the ratio of metastatic to resected lymph nodes
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In this study, an effort was made to validate possible
changes in the TNM system assuming the importance of
the number of metastatic lymph nodes or the ratio of
metastatic nodes to removed nodes in staging NSCLC.
A homogeneous group of patients was selected, con-
secutively operated in a high-volume center, after the
anatomical resections of lung parenchyma and the intra-
operative removal at least 6 lymph nodes in order to
verify the importance of the non-anatomical classifica-
tion of N descriptor. The extent of lymph node resection
raises a lot of discussions, however, there is no doubt
that at least a systemic lymph node sampling is needed
for staging N descriptor and most authors recommend
mediastinal lymphadenectomy [10, 15, 16]. In literature
there is no agreement regarding the minimum number
of lymph nodes to be removed. It is recommended by
ESTS to remove at least six nodes, according to the data
compiled from the SEER database 11–16 nodes, according
to Doddoli et al. 10 nodes and according to Wu et al. at
least 15 nodes [10, 17–19]. In our study during the
Fig. 1 Survival according to current nodal classification (CLN)
Fig. 2 Survival according to new classification based on the number of metastatic lymph nodes (NLN)
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operation 23.4 lymph nodes were removed (10.6 % of
patients had less than 11 nodes removed) which seems to
be enough to stage N descriptor accurately.
In our study we do not confirm the hypothesis that
assumes the better prognostic value of staging N2 de-
scriptor based on the number of metastatic nodes or the
ratio determining their proportions. While studying a
group of patients after systematic lymph node dissection,
it was found that the highest hazard ratio of the evalu-
ation of N2 descriptor refers to the current classification
of N2 descriptor. Despite the small differences between
the various classifications, it cannot be stated that adding
new elements to the classification of N descriptor in the
new 8th edition of TNM will bring prognostic benefits. In
the last years, a few studies have been published which
assume that the effect of the number of removed lymph
nodes or the ratio determining the number of metastatic
nodes on survival is significant and better than the current
classification [20–23]. However, these studies relate to
long periods of observations mainly from the 80’s and 90’s
of the last century, when the approach to preoperative
staging, the extent of mediastinal lymphadenectomy, the
evaluation of mediastinal nodes, the removal of metastatic
lymph nodes from mediastinum (even “bulky disease”),
the use of neoadjuvant chemotherapy for metastases to
mediastinal lymph nodes were slightly different from that
one in the middle of the last decade. Perhaps before we
start to look for a better classification of N2 descriptor
including its heterogeneity we should consider how to
systematize and standardize the removal of lymph nodes in
patients treated surgically because sometimes, even in one
thoracic surgery center, the extent of lymphadenectomy
may vary completely [24]. The studies, in which a higher
prognostic value of metastatic nodes has been proved, as-
sume the division of N descriptor into several subgroups
depending on the ranges into which metastatic lymph
nodes were divided [20, 21, 23]. Aiming at a simple
method of classification of N descriptor, in our study we
tried to determine a dividing line of metastatic nodes de-
fined by the median. In our study, the median was 3 meta-
static nodes, in a not much bigger population a similar
dividing line was defined by Matsuguma (median 2 nodes)
[22]. In studies on large populations, the median value is
likely to change only a little and will range between 2–3
metastatic nodes. In order to avoid further development of
the TNM system with numerous subgroups of N descriptor
and making it more complex and less clear, it is justified
Fig. 3 Survival according to new classification based on the ratio of metastatic lymph nodes (RLN)
Table 2 Comparison of hazard ratios of the current and new
nodal classifications included in the multivariate analysis










CLN current nodal classification, NLN new classification based on the number
of metastatic lymph nodes, RLN new classification based on the ratio of
metastatic to resected lymph nodes, HR hazard ratio
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taking into consideration the value of median in further
study on the significance of the number of metastatic
lymph nodes. The suggested division of the number of
metastatic lymph nodes into groups: 1–3, 4–6, >6 [21],
1–4, 4–14, >14 [23], 1–3, 4–6, 7–9, ≥10 [20] can be
found in literature. It seems that even basing on the
studies on large populations, it will be difficult to estab-
lish several dividing lines of the number of metastatic
nodes, as well as, it is currently difficult to define the
minimum number of nodes that must be removed to per-
form appropriate staging of N descriptor. In addition, re-
gardless of the size of nodes in imaging examinations,
many of the centers have introduced minimally invasive
techniques such as EBUS and EUS to routinely preopera-
tive staging of N descriptor. This will probably cause that
the chances to diagnose a several or even more metastatic
lymph nodes in patients in the postoperative evaluation
will be considerably reduced. However, it should be noted
that although the prognostic power is weaker than the
current one, the new classifications are also a signifi-
cant and strong prognostic factor in a surgically treated
NSCLC (p <0.001) in the evaluation of both N1 and N2
descriptors. Therefore it seems that we should not
erase their significance. The study was currently carried
out on a relatively small population which is its limita-
tion. Though it is possible that studies on bigger popu-
lations will allow to include the ratio or the number of
metastatic lymph nodes to the current classification
system of N descriptor as its complement but not as a
complete substitute.
It should be also taken into account that the current
classification of N descriptor based on the location of
nodes is used not only in the postoperative but also in
the preoperative evaluation as it is easy to evaluate the
location of nodes in imaging studies before the planned
surgical treatment. When introducing new rules for the
classification of N descriptor, there are some discrepancies
between clinical and pathological staging of a disease. The
complexity and difficulty of the pathological classification
of lymph nodes resulting from the heterogeneity of N
descriptor cause that in the future neither a location,
quantity nor a ratio of metastatic nodes will be important
in the decision on the adjuvant treatment. Probably the
evaluation of nodes for novel molecular tumor cell
markers determines a tumor aggressiveness, a status of
N descriptor as well as, whether the patient should be
treated after surgery or observed [25, 26]. In each case
however, it will be necessary to remove an appropriate
number of lymph nodes for pathological diagnostics.
Conclusion
In conclusion, despite the significant prognostic power,
it cannot be assumed that new classifications defining
N descriptor are superior over the currently one.
Nevertheless, it should be borne in mind that there are
some deficiencies in the current classification, there-
fore further studies on its improvement are needed,
regarding both the planned adjuvant treatment as well
as, raising the rank of removing a proper number of
lymph nodes to stage a disease appropriately.
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